Respiratory Medicine
Volume 103, Issue 8 , Pages 1098-1113 , August 2009

The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update

  • Stephen Holgate

      Affiliations

    • Infection, Inflammation and Repair Division, School of Medicine, University of Southampton, D level Centre Block (MP810), Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 (0) 23 8079 6960; fax: +44 (0) 23 8070 1771.
    • ,
  • Roland Buhl

      Affiliations

    • Mainz University Hospital, 55131 Mainz, Germany
    • ,
  • Jean Bousquet

      Affiliations

    • Hôpital Arnaud de Villeneuve, FR-34000 Montpellier, France
    • ,
  • Nicola Smith

      Affiliations

    • Novartis Horsham Research Centre, Horsham, RH12 5AB, UK
    • ,
  • Zoya Panahloo

      Affiliations

    • Novartis Horsham Research Centre, Horsham, RH12 5AB, UK
    • ,
  • Pablo Jimenez

      Affiliations

    • Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936-1080, USA

Received 20 October 2008 ,Accepted 12 March 2009.

References 

  1. Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children. Issue 2. Art. No.: CD003559 Cochrane Database Syst Rev. 2006;
  2. Prenner BM. Asthma 2008: targeting immunoglobulin E to achieve disease control. J Asthma. 2008;45:429–436
  3. Price D. The use of omalizumab in asthma. Prim Care Respir J. 2008;17:62–72
  4. Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P. Safety and tolerability of omalizumab. Clin Exp Allergy, in press. doi: 10.1111/j.1365-2222.2009.03214.x.
  5. Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol. 2005;115:459–465
  6. Sullivan SD, Turk F. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma. Allergy. 2008;63:670–684
  7. Global Initiative for Asthma. Global strategy for asthma management and prevention. Issued January 1995 (NIH Publication No. 02-3659); updated 2002, 2003, 2004, 2005, 2006, 2007. Available at: www.ginasthma.org.
  8. American Thoracic Society . Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med. 2000;162:2341–2351
  9. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am J Respir Crit Care Med. 2004;170:836–844
  10. Fish J, Miller K, Bradley S, Szefler S. Characteristics of omalizumab-treated patients in the EXCELS study. Am J Respir Crit Care Med. 2008;177(Abstracts issue):A613
  11. Dolan CM, Fraher KE, Bleecker ER, et al. Design and baseline characteristics of the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol. 2004;92:32–39
  12. Guite HF, Dundas R, Burney PGJ. Risk factors for death from asthma, chronic obstructive pulmonary disease, and cardiovascular disease after a hospital admission for asthma. Thorax. 1999;54:301–307
  13. Hartert TV, Speroff T, Togias A, et al. Risk factors for recurrent asthma hospital visits and death among a population of indigent older adults with asthma. Ann Allergy Asthma Immunol. 2002;89:467–473
  14. Tough SC, Hessel PA, Ruff M, Green FH, Mitchell I, Butt JC. Features that distinguish those who die from asthma from community controls with asthma. J Asthma. 1998;35:657–665
  15. Juniper EF, Wisniewski ME, Cox FM, Emmett AH, Nielsen KE, O'Byrne PM. Relationship between quality of life and clinical status in asthma: a factor analysis. Eur Respir J. 2004;23:287–291
  16. Turk F, Piercy J, Benford M. The human impact of severe persistent allergic asthma; results of a multinational study. Value Health. 2005;8:A32
  17. Godard P, Chanez P, Siraudin L, Nicoloyannis N, Duru G. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J. 2002;19:61–67
  18. Antonicelli L, Bucca C, Neri M, et al. Asthma severity and medical resource utilisation. Eur Respir J. 2004;23:723–729
  19. Turk F, Kay S, Higgins V. The economic and human impact of poor control in patients with severe persistent allergic asthma: results from a multinational study. Thorax. 2005;60(Suppl. II):P21
  20. Serra-Battles J, Plaza V, Morejón E, Comella A, Brugués J. Costs of asthma according to the degree of severity. Eur Respir J. 1998;12:1322–1326
  21. ENFUMOSA . The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J. 2003;22:470–477
  22. Hammad H, Lambrecht BN. Dendritic cells and epithelial cells: linking innate and adaptive immunity in asthma. Nat Rev Immunol. 2008;8:193–204
  23. Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol. 2003;111:S486–S494
  24. Novak N, Bieber T. Allergic and nonallergic forms of atopic diseases. J Allergy Clin Immunol. 2003;112:252–262
  25. Jaffar Z, Roberts K, Pandit A, Linsley P, Djukanović R, Holgate S. B7 costimulation is required for IL-5 and IL-13 secretion by bronchial biopsy tissue of atopic asthmatic subjects in response to allergen stimulation. Am J Respir Cell Mol Biol. 1999;20:153–162
  26. Djukanović R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004;170:583–593
  27. MacGlashan DW, Bochner BS, Adelman DC, et al. Down-regulation of Fc(ɛ)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997;158:1438–1445
  28. Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat Rev Immunol. 2008;8:205–217
  29. Lin H, Boesel KM, Griffith DT, et al. Omalizumab rapidly decreases nasal allergic response and FcɛRI on basophils. J Allergy Clin Immunol. 2004;113:297–302
  30. Humbles AA, Lloyd CM, McMillan SJ, et al. A critical role for eosinophils in allergic airways remodeling. Science. 2004;305:1776–1779
  31. Lee JJ, Dimina D, Macias MP, et al. Defining a link with asthma in mice congenitally deficient in eosinophils. Science. 2004;305:1773–1776
  32. Presta L, Shields R, O'Connell L, et al. The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem. 1994;269:26368–26373
  33. Shields RL, Whether WR, Zioncheck K, et al. Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol. 1995;107:308–312
  34. Genentech Inc. Omalizumab (Xolair®) full prescribing information, July 2007. Available at: http://www.gene.com/gene/products/information/immunological/xolair/insert.jsp. Accessed 02 June 2008.
  35. Boulet LP, Chapman KR, Côté J, et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med. 1997;155:1835–1840
  36. Casale TB, Bernstein IL, Busse WW, et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol. 1997;100:110–121
  37. Ädelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2000;106:253–259
  38. Hochhaus G, Brookman L, Fox H, et al. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin. 2003;19:491–498
  39. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60:309–316
  40. Humbert M, Ayre G, Fox H, Blogg M. Number needed to treat to prevent one medically significant event per year with add-on omalizumab: INNOVATE. EAACI Abstract Book. 2006;41:125
  41. Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy. 2005;60:302–308
  42. Corren J, Casale T, Lanier BQ. Omalizumab is well tolerated in adolescent/adult patients (>12 years) with moderate-to-severe asthma. J Allergy Clin Immunol. 2005;115:S75
  43. Limb S, Starke P, Lee C, Chowdhury B. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol. 2007;120:1378–1381
  44. Price KS, Hamilton RG. Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma Proc. 2007;28:313–319
  45. Lieberman P. The unusual suspects: a surprise regarding reactions to omalizumab. Allergy Asthma Proc. 2007;28:259–261
  46. Chipps B. Systemic reaction to omalizumab. Ann Allergy Asthma Immunol. 2006;97:267
  47. Cox L, Platts-Mills TA, Finegold I, Schwartz LB, Simons FE, Wallace DV. American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol. 2007;120:1373–1377
  48. Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology . The diagnosis and management of anaphylaxis: an updated practice parameter. J Allergy Clin Immunol. 2005;115(Suppl.):S483–S523
  49. Simons FE. Anaphylaxis, killer allergy: long-term management in the community. J Allergy Clin Immunol. 2006;117:367–377
  50. National Heart Lung and Blood Institute. Expert Panel Report 3 (EPR3): Guidelines for the diagnosis and management of asthma 2007. Available at: http://www.nhlbi.nih.gov/guidelines/asthma/index.htm. Accessed 02 June 2008.
  51. Liu J, Lester P, Builder S, Shire J. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry. 1995;34:10474–10482
  52. US Food and Drug Administration . Center for Biologics Evaluation and Research. BLA STN 103976/0, briefing document on safety. Rockville, MD: Genentech Inc.; 2003;Department of Health and Human Services
  53. Pilette C, Coppens N, Houssiau F, Rodenstein D. Severe serum sickness-like syndrome after omalizumab therapy for asthma. J Allergy Clin Immunol. 2007;120:972–973
  54. Fernández C, Busse W, Reisner C, Gupta N. Clinical data do not suggest a causal relationship between omalizumab therapy and cancer. Proc Am Thorac Soc. 2005;2:A359
  55. Cruz AA, Lima F, Sarinho E, et al. Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection. Clin Exp Allergy. 2007;37:197–207
  56. Bousquet J, Rabe K, Humbert M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med. 2007;101:1483–1492
  57. Martin C, Freeman P, Blogg M. Pre-treatment specific IgE levels are not useful in predicting a response to omalizumab therapy. J Allergy Clin Immunol. 2008;121:S171
  58. Molimard M, de Blay F, Didier A, Le Gros V. Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respir Med. 2008;102:71–76
  59. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax. 1992;47:76–83
  60. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in the disease specific quality of life questionnaire. J Clin Epidemiol. 1994;47:81–87
  61. Schatz M, Sorkness CA, Li JT, et al. Asthma Control Test: Reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol. 2006;117:549–556
  62. Niven R, Chung KF, Panahloo Z, et al. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study. Respir Med. 2008;102(10):1371–1378
  63. Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy. 2004;59:701–708
  64. Thomson N, Niven R, Heaney L, Greening A. Development of an algorithm for the assessment of response to treatment with omalizumab. Thorax. 2007;62(Suppl. 3):A99, P94
  65. Holgate ST. How to evaluate a patient's response to anti-IgE. Eur Respir Rev. 2007;16:78–84
  66. Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest. 2004;125:1378–1386
  67. Ayre G, Anthonissen C, Martin C, Turk F, Thomas K. Assessment of a responder identification treatment algorithm for omalizumab in a naturalistic setting. Eur Respir J. 2007;30(Suppl. 51):623s, P3654
  68. Buhl R, Solèr M, Matz J, et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J. 2002;20:73–78
  69. Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol. 2003;91:154–159
  70. Bousquet J, Chung F, Tunon-de-Lara JM, et al. Retreatment with omalizumab, an anti-IgE monoclonal antibody, is well tolerated in patients with severe allergic asthma. Allergy. 2003;58(Suppl.):2, A4
  71. Slavin R, Ferioli C, Tannenbaum S, et al. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing immunoglobulin-E and decreasing pharmacokinetic concentrations. J Allergy Clin Immunol 2009;123(1):107–113, e3.
  72. Holgate ST, Chuchalin AG, Hébert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy. 2004;34:632–638
  73. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108:184–190
  74. Solèr M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18:254–261
  75. Wenzel S, Hébert J, Buhl R, et al. Add-on omalizumab therapy significantly reduces asthma exacerbations in patients with severe persistent asthma requiring maintenance oral corticosteroids: a pooled analysis. Proc Am Thorac Soc. 2005;2:A358
  76. Zeldin R, Massanari M, Maykut R, et al. Omalizumab reduced the need for steroid bursts in asthmatics concomitantly using leukotriene receptor antagonists (LTRAs). J Allergy Clin Immunol. 2006;117:S280
  77. Korn S, Thielen A, Seyfried S, Kornmann O, Buhl R. Omalizumab in patients with uncontrolled, severe persistent allergic (IgE-mediated) asthma in a real-life setting in Germany. Am J Respir Crit Care Med. 2008;177(Abstracts issue):A612
  78. Niven R. A UK survey of oral corticosteroid use in patients treated with omalizumab. Thorax. 2007;62(Suppl. 3):A98, P91
  79. Marcus P. Incorporating anti-IgE (omalizumab) therapy into pulmonary medicine practice: practice management implications. Chest. 2006;129:466–474
  80. Bousquet J, Vignola AM, Demoly P. Links between rhinitis and asthma. Allergy. 2003;58:691–706
  81. Price D, Zhang Q, Kocevar S, et al. Effect of concomitant diagnosis of allergic rhinitis on asthma-related health care use in adults. Clin Exp Allergy. 2005;35:282–287
  82. Casale TB, Condemi J, LaForce C, et al. Effect of omalizumab on symptoms of allergic rhinitis. A randomized controlled trial. JAMA. 2001;286:2956–2967
  83. Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy. 2004;59:709–717
  84. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy. 1991;21:77–83
  85. Humbert M, Boulet LP, Niven RM, Panahloo Z, Blogg M, Ayre G. Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis. Allergy 2009;64(1):81–84.
  86. National Institute For Health And Clinical Excellence. Final appraisal determination omalizumab for severe persistent allergic asthma. 2007. Available from: http://guidance.nice.org.uk/download.aspx?o = 450310. Accessed 18 September 2007.
  87. Nopp A, Johansson SG, Ankerst J, Palmqvist M, Oman H. CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment. Allergy. 2007;62:1175–1181
  88. Robinson DS, Campbell DA, Durham SR, et al. Systematic assessment of difficult-to-treat asthma. Eur Respir J. 2003;22:478–483

PII: S0954-6111(09)00089-4

doi: 10.1016/j.rmed.2009.03.008

Respiratory Medicine
Volume 103, Issue 8 , Pages 1098-1113 , August 2009

Article Tools

* Image Usage & Resolution